The research company Chosa Oncology has decided on a directed issue of units of initially approximately SEK 7.3 million before costs. The issue comprises approximately 9 million units at a price of SEK 0.82 per unit and is aimed at existing shareholders as well as external investors. Each unit consists of one share and one warrant of series TO3 issued free of charge. Upon full exercise of the warrants in November 2026, the company could receive an additional approximately SEK 9.2 million.The capital injection is expected to finance operations until the third quarter of next year. "Our latest clinical results confirm the clinical and commercial strength of Platin-DRP. The capitalization gives us financial flexibility to focus on market approval, partnerships, and broad clinical implementation. With a validated and scalable technology, we address a significant medical need and create good conditions for continued value creation," says Peter Buhl Jensen, CEO of Chosa Oncology, in a comment. The proceeds from the issue will be used, among other things, for studies, sales, partnerships, market preparations, alignment with clinical guidelines, and scaling up logistics and the user experience. Administrative costs are also included. The issue entails an initial dilution of approximately 10.2 percent and a total of approximately 18.5 percent upon full exercise of the warrants.